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AP-1 and NF-𝜅B inhibitors, namely, DTCM-G and DHMEQ, were investigated in male Wistar rats with severe colitis, induced by
TNBS. The animals were randomized into 3 groups. The control group received 0.5mL of 0.5% of the vehicle i.p., the DTCM-G
group received 22.5mg/kg body weight DTCM-G in 0.5% i.p., and the DHMEQ group received 15mg/kg body weight DHMEQ
i.p., all twice daily for 5 days. The body weight losses and mortality rates were significantly higher in the control group than those
in DTCM-G-treated and DHMEQ-treated groups. The endoscopic inflammation scores in the control, DTCM-G-treated, and
DHMEQ-treated groups were 6.3 ± 0.7, 1.0 ± 0.3, and 0.7 ± 0.3, respectively (P = 0.004 and 0.02, resp.). The inflammation scores
as assessed by the macroscopic appearance were 4.3 ± 0.8, 0.7 ± 0.3, and 1.2 ± 0.4 in the control, DTCM-G-treated, and DHMEQ-
treated groups, respectively (P = 0.01 and 0.009, resp.). The histopathological inflammation scores were 6.4 ± 0.7, 2.0 ± 1.0, and 2.2
± 0.6 in the control, DTCM-G-treated, and DHMEQ-treated groups, respectively (P = 0.03 and 0.01, resp.). It was concluded that
DTCM-G and DHMEQ exhibit strong anti-inflammatory and anticancer activities with no apparent toxicity, which make them
excellent drug candidates for clinical use in inflammatory bowel diseases.
1. Introduction
Inflammatory bowel diseases (IBDs) comprise two main
distinct disorders with independent clinicopathologies and
unknown etiologies [1]. These disorders, Crohn’s disease
(CD) and ulcerative colitis (UC), exhibit fairly distinct
organ specificities and histopathological characteristics [1].
Whereas CD inflammation is transmural and occurs in any
part of the gastrointestinal tract (although the terminal ileum
is mainly affected), UC inflammation is more superficial
and affects the colonic mucosa [2] IBDs affects as many as
1.4 million individuals in North America and 2.2 million
individuals in Europe, with a reported incidence of 3–20 new
cases per 100,000 persons [3–6].
The onset of IBDs occursmostly at a young age and causes
lifelong illness [7]. IBDs considerably reduce the quality of
life due to the patients finding the symptoms embarrassing
and humiliating, and that these symptoms interfere with
education, working abilities, and social interactions [7].
Furthermore, IBDs represent an economic burden on society
[6]. These diseases are chronic and have considerably diverse
clinical courses, with frequent relapses or chronic active
disease in some patients, whereas others experience years of
virtually complete remission [7].
Treatments with 5-aminosalicylates (introduced in the
1930s) and corticosteroids (introduced in the 1950s) are
beneficial for many IBD patients but are not effective for
most patients over the long term [8]. Thiopurine analogues,
mercaptopurine, and azathioprine as well as methotrexate
have been also used. However, both short- and long-term
side effects limit their use [1, 2, 8]. Biological agents such as
antibodies against tumor necrosis factor 𝛼 (TNF𝛼) have been
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used for 2 decades, but only about 65%ofUC andCDpatients
respond to such treatment. Surgical treatment remains the
only option for many IBDs patients.This treatment can result
in malnutrition and eventual short-bowel syndrome in CD
patients and severe diarrhea in UC patients, in addition to
the other operation complications [7–12].
There are several animal models of IBDs [6–13]. These
models comprise chemically induced colitis or mutant mice
such as interleukin-2 (IL-2)/IL-10-knockout mice. While
none of the models exactly reproduce the human IBDs, they
are extremely valuable in allowing research into the com-
plexity of IBDs and testing the efficacy of anti-inflammatory
agents. Trinitrobenzene sulfonic acid (TNBS)-induced colitis
has been considered to closely mimic the clinical and mor-
phological features of human CD [13].
The piperidine compound 9-methylstreptimidone has
been isolated from Streptomyces sp. [14]. 3-[(dodecylthiocar-
bonyl)-methyl]-glutarimide (DTCM-G) is a synthetic deriva-
tive of 9-methylstreptimidone that has been shown to possess
potent anti-inflammatory activity in animal experiments
[15]. DTCM-G exerts a potent anti-inflammatory effect
and has been found to inhibit lipopolysaccharide-induced
activation of macrophages possibly via suppression of AP-1
[15]. Recently, this compound was shown to increase graft
survival markedly in mice in heart transplantation model
whenused togetherwith tacrolimus orDHMEQ[16].Nuclear
factor 𝜅B (NF-𝜅B) is the transcription factor that binds to
the 𝜅B sequence found in DNA. NF-𝜅B is a heterodimer
consisting of Rel-family proteins including p65, cRel, RelB,
p50, and p52. NF-𝜅B activation occurs via canonical and
noncanonical signaling pathways: the canonical pathway is
mainly involved in natural immunity and most types of
inflammation, while the noncanonical one is mainly involved
in B-cell maturation and autoimmune diseases [17]. Excessive
activation of NF-𝜅B leads to activation of immune cells
and macrophages, resulting in inflammation [17]. Dehydrox-
ymethylepoxyquinomicin (DHMEQ) is a newly designed
NF-𝜅B inhibitor with a low molecular weight. Its structure
was modified from that of the antibiotic epoxyquinomicin
C. Epoxyquinomicin has been synthesized from the culture
broth of Amycolatopsis sp. MK299-95F4, which was isolated
from a soil sample collected at Sendai City,Miyagi Prefecture,
Japan [17, 18]. Both epoxyquinomicin and DHMEQ are very
low toxic compounds in animals. Its molecular target is NF-
𝜅B component itself, and it inhibits DNA binding of NF-𝜅B
[19]. DHMEQ has shown potent anti-inflammatory activity
in many animal models including rheumatoid arthritis, renal
inflammation, and organ transplantation [17].
The present study investigated the effects of these two
novel anti-inflammatory substances (i.e., DTCM-G and
DHMEQ) on severe colitis induced in rats by TNBS.
2. Materials and Methods
2.1. Rats. Male Wistar rats (Hannover GALAS, Taconic
Farms, Denmark, Europe), with a mean body weight of
279.2 g (range 228–382 g) were housed singly in Macrolon III
cages and fed ad libitum on a standard diet (B&K Universal,
Nittedal, Norway) consisting of cereal products (88.5%), soy
protein (6%), animal protein (2.5%), soy oil (0.5%), and
vitamin, mineral, and amino-acid supplementation (2.5%).
Water was also given ad libitum. The animals were main-
tained at 21 ± 1∘C and relative humidity 55 + 5% under
a 12/12 h light/dark cycle. A grid floor was used when the
animals were fasted to prevent them from eating their feces.
The study was carried out in accordance with the
Directive for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes of the European
Union (86/609/EEC), in compliance with the Declaration
of Helsinki. The Local Ethical Committee for Experimental
Animals approved the protocols of the study.
2.2. Study Design. The animals were left at least 7 days in
the animal house to acclimatize before the experiment. TNBS
were applied for 3 days to induce colitis. In the fourth day,
the animals were randomized into 3 groups of 12 animals
each, constituting the controls and those treatedwithDTCM-
G and DHMEQ. The control group received 0.5mL of 0.5%
carboxymethyl cellulose (CMC) i.p. twice daily fo 5 days, the
DTCM-G group received 22.5mg/kg body weight DTCM-G
in 0.5% CMC i.p. twice daily for 5 days, and the DHMEQ
group received 15mg/kg DHMEQ in 0.5% CMC i.p. twice
daily for 5 days. At the end of the experiment, a colonoscopy
was performed before killing each animal by the inhalation
of CO
2
, and a postmortem laparotomy was carried out and
the abdomen and colonwere examined. Tissue samples taken
from the colon were examined histologically. DTCM-G and
DHMEQ were synthesized as described previously [14, 15,
20–22].
2.3. Induction of Colitis by TNBS. Colitis was induced by
TNBS as described previously [23]. Briefly, rats were fasted
for 24 h prior to TNBS administration. A single dose of TNBS
(Sigma-Aldrich, Logistic, Germany) at 25mg/animal in 50%
ethanol solution (0.5mL/rat) was introduced into the colon
by an 8.5 cm long probe with a 2.5mm round Teflon tip
under light anesthesia (isoflurane, Merck Pharmaceutical,
West Point, PA, USA). The animals were monitored several
times daily until recovery. Animals with any sign of pain
were injected s.c. with 1mL of Temgesic solution (contain-
ing 0.3 Temgesic/mL, Merck Pharmaceutical). Animals that
showed signs of suffering or severe illness were killed by
inhalation of CO
2
.
2.4. Colonoscopy and Assessments of the Macroscopic Appear-
ance. Colonoscopy and mucosal biopsies were performed
as described previously [23]. Briefly, the rats were fasted
for 24 h and received gastric doses of 1mL and 2mL of
Picoprep (Ferring Pharmaceuticals, Oslo, Norway) at 12 h
and 24 h during the fasting period, respectively. Picoprep
was introduced via an 8.5 cm long feeding gauge with a
2.5mm round Teflon tip (AgnTho’s, Lidingo¨, Sweden). The
rats were anesthetized by inhalation of isoflurane prior to and
during colonoscopy. For the colonoscopy they were placed
in a supine position and secured to an acrylic surgical table
(World Precision Instruments, Sarasota, FL, USA).The video
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gastroscope used had a 4.9mm outer diameter, 210∘/120∘ of
up/down angular motion, a 103 cm working length, 140∘ view
field, and a 2mm working channel (GIF-N180, Olympus,
Tokyo, Japan).The endoscopic grading scale of inflammation
described by Vermeulen and colleagues was used [24]. This
scale comprises the following five subscales and has a total
score ranging from 0 to 19: degree of inflammation (scored
0–6), extent of disease (scored 0–10), stenosis (scored 0 or 1),
edema (scored 0 or 1), and active bleeding (scored 0 or 1).
After the procedure, the animals were allowed to recover
from anesthesia and were monitored for about an hour. The
animals were then killed and the macroscopic appearance of
the colon was assessed using the macroscopic scoring system
of Vermeulen and colleagues as adapted from Wallace and
Keenan [24, 25]. In this scoring system, the inflammation
is assessed on the following scale from 0 to 10 based on
ulceration, inflammation, and extent of disease: 0 = normal
aspect of the mucosa, 1 = localized hyperemia without
ulcerations, 2 = ulceration, 3 = ulceration with thickening of
bowel wall at one site, 4 = two or more sites of ulceration
and thickening of the bowel wall, 5 = major sites of damage
extending <2 cm along the length of the colon, and 6–10 =
damage extending >2 cm (with the score increasing by 1 for
each centimeter of damaged tissue). Tissue samples taken
from the colon were examined histologically.
2.5. Histopathological Examination. The tissue samples taken
during postmortem laparotomy were fixed in 4% buffered
paraformaldehyde overnight, embedded in paraffin, and
cut into 5 𝜇m-thick sections. The sections were stained by
hematoxylin-eosin, and inflammation was evaluated using
the scoring system of Hunter and colleagues as described by
Vermeulen and colleagues [24, 26]. The total score, which
ranges from 0 to 8, is summation of four parameters: inflam-
matory infiltration (scored 0–3), number of gutwalls involved
(scored 0–3), damage to mucosal architecture (scored 0 or 1),
and edema (scored 0 or 1).
2.6. Statistical Analysis. The difference in survival was tested
by a log-rank (Mantel-Cox) test, log-rank test for trend. The
difference between the control, DTCM-G-, and DHMEQ-
treated groups was tested by the Kruskal-Wallis nonparamet-
ric test with Dunn’s test as a posttest. The data are presented
as mean ± SEM values, and the level of statistical significance
was set at 𝑃 < 0.05.
3. Results
3.1. BodyWeight and Survival. At the start of the experiment,
the bodyweights of rats in the control, DTCM-G-treated, and
DHMEQ-treated groups were 272.5 ± 9.9 g, 255.3 ± 7.5 g,
and 299.6 ± 12.5 g, respectively; the corresponding body
weight losses at the experiment end-point were 20.5 ± 1.1%,
1.8 ± 0.6%, and 1.8 ± 0.8%. There was no difference in the
body weight between the control and treatment groups at
the start of the experiment (𝑃 = 0.07). The body weight
losses at the end-point of the experiment differed significantly
between controls, DTCM-G-treated, and DHMEQ-treated
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Figure 1: The body weight loss at the end-point of the experiment
in controls, DTCM-G-treated, and DHMEQ-treated groups. ∗∗∗𝑃 <
0.0001 versus controls.
Endoscopic score
0
2
4
6
8
Th
e t
ot
al
 en
do
sc
op
ic
 sc
or
e (
m
ea
n 
±
 S
EM
)
Controls DTCM-G DHMEQ
∗∗
∗
Figure 2: Total endoscopic inflammation scores at the end-point
of the experiment in the control, DTCM-G-treated, and DHMEQ-
treated groups. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus controls.
groups (𝑃 < 0.0001). Multiple comparisons showed that the
bodyweight losses differed significantly between controls and
DTCM-G-treated, and DHMEQ-treated groups (𝑃 < 0.001,
in both) (Figure 1).
The percentages of animals that died due to spontaneous
death or being killed for animal-welfare reasons between the
start and end-point of the experiment were 42% (5 of 12),
17% (2 of 12), and 8% (1 of 12) in the control, DTCM-G-
treated, and DHMEQ-treated groups, respectively. The log-
rank (Mantel-Cox) test and log-rank test for trend showed
that the survival rate was significantly higher in DTCM-G-
treated and DHMEQ-treated groups than in controls (𝑃 <
0.05 and <0.01, resp.).
3.2. Endoscopic and Macroscopic Appearance. The endo-
scopic inflammation scores in the control, DTCM-G-treated,
and DHMEQ-treated groups were 6.3 ± 0.7, 1.0 ± 0.3, and
0.7 ± 0.3, respectively (Figures 2 and 3).Multiple comparisons
revealed a statistically significant difference between the three
groups (𝑃 = 0.004).These scores differed between the control
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Figure 3: Endoscopic appearances of control rats ((a) and (b)), a rat treated with DTCM-G (c), and a rat treated with DHMEQ (d). Narrow-
band imaging (NBI) was used, which provides twice the viewable distance and offers a much greater contrast between the blood vessels and
the mucosa.
group and the DTCM-G- and DHMEQ-treated groups (𝑃 =
0.004 and 0.02, resp.).
The inflammation scores as assessed by the macroscopic
appearance of the colon were 4.3 ± 0.8, 0.7 ± 0.3, and 1.2 ±
0.4 in the control, DTCM-G-treated, and DHMEQ-treated
groups, respectively, (Figures 4 and 5). Multiple comparisons
revealed a statistically significant difference between the three
groups (𝑃 = 0.001).These scores differed between the control
group and the DTCM-G- and DHMEQ-treated groups (𝑃 =
0.01 and 0.009, resp.).
3.3. Histopathological Score. The histopathological inflam-
mation scores were 6.4 ± 0.7, 2.0 ± 1.0, and 2.2 ± 0.6 in
the control, DTCM-G-treated, and DHMEQ-treated groups,
respectively, (Figures 6 and 7).Multiple comparisons revealed
a statistically significant difference between the three groups
(𝑃 = 0.002). These scores differed between the control group
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Figure 4: Total macroscopic inflammation scores in control and
treated rats at the end-point of the experiment. ∗𝑃 < 0.05 and
∗∗
𝑃 < 0.01 versus controls.
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Figure 5: Macroscopic appearances of the colons of control rats ((a) and (b)), a rat treated with DTCM-G (c), and a rat treated with DHMEQ
(d).
Histopathological score
0
2
4
6
8
Th
e t
ot
al
 h
ist
op
at
ho
lo
gi
ca
l s
co
re
 (m
ea
n 
±
 S
EM
)
Controls DTCM-G DHMEQ
∗
∗
Figure 6: Total histopathological scores at the end-point of the
experiment in the control, DTCM-G-treated, and DHMEQ-treated
groups. ∗𝑃 < 0.05 versus controls.
and the DTCM-G- and DHMEQ-treated groups (𝑃 = 0.03
and 0.01, resp.).
4. Discussion
TBNS-induced colitis is considered to be an animal model
that mimics human CD [27, 28]. Similar to human CD,
the animals have bloody diarrhea and weight loss. The
inflammation is transmural and can occur in any part
of the gastrointestinal tract. However, the doses of TNBS
used to induce colitis and the methodologies differ between
studies [29–34]. The inherent variability in TNBS lots and
among animals used necessitates repeated dose ranging and
adjustment [13]. The animals, TNBS lot, and TNBS dosage
used in this study were the same as those that we used in
a previous study in which the conditions resulted in severe
colitis that was equivalent to human fulminant colitis [23].
The attraction of immune cells to a site of inflammation
and their activation are regulated by different cytokines and
chemokines, which in turn are regulated by transcription
factors such as AP-1 and NF-𝜅B [35–37]. DTCM-G is an
AP-1 inhibitor that inhibits the activation of macrophages
and proinflammatory cytokines [15, 16]. Moreover, DTCM-
G has been found to inhibit graft rejection in experimental
heart transplantation [15, 16]. DHMEQ inhibits the nuclear
translocation of NF-𝜅B and directly binds to the Rel-family
components to inhibit their DNA-binding activity [17, 19,
38]. DHMEQ has been reported to have a high potency
in suppressing inflammation in animal models of vari-
ous inflammatory diseases including rheumatoid arthritis,
inflammatory injury to the kidney, and IBDs [17, 22, 39–42].
The present study found that the body weight loss was
less and the survival rate was higher than in controls in rats
with severe colitis induced by TNBS the following treatment
with DTCM-G and DHMEQ. This increased survival was
due to a reduction in intestinal inflammation, as indicated
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Figure 7: Photomicrographs of the colons of control rats ((a) and (b)), a rat treated with DTCM-G (c), and a rat treated with DHMEQ (d).
by the decreased inflammation score detected by endoscopic,
macroscopic, and histopathological methods.These observa-
tions are in line with previously reported effects of DHMEQ
on colitis induced by TNBS and dextran sulfate sodium in
mice [42]. That study found that proinflammatory cytokines
such as IL-1𝛽, TNF𝛼, IL-6, IL-12p40, IL-17, and MCP-1
(monocyte chemotactic protein-1) were suppressed following
the administration of DHMEQ.
In addition to their anti-inflammatory effects, DTCM-
G and DHMEQ possess unique pharmacokinetic criteria.
The administration of DHMEQ either i.p. or i.v. does not
result in a detectable concentration in the blood [17]. The
i.p. administration of DHMEQ leads to a high concentration
in the peritoneal cavity within 5min and a rapid decrease
after 30min, though almost no DHMEQ can be detected in
the bloodstream [17]. It has been proposed that DHMEQ
does not enter the systemic circulation, instead exerting
its effects locally in the peritoneal cavity [17]. Umezawa
proposed the following hypothesis for explaining the anti-
inflammatory effect of DHMEQ at sites distant from the
peritoneal cavity: macrophages differentiate in the peritoneal
cavity prior to migrating to inflammation sites, and the
peritoneal cavity is an extravascular culture chamber for the
maturation of microphages [17, 43]. Furthermore, natural
helper cells, which activate B-cell differentiation, exist only
in the mesentery of the peritoneal cavity [44]. DHMEQ
is therefore likely to be taken up by these immune cells
prior to their migration to inflammation sites [17]. This may
explain why DHMEQ has not shown any toxicity in animal
experiments, in contrast to other NF-𝜅B inhibitors [17].
Several drugs currently used in clinic against IBDs, such
as azathioprine and anti-TNF𝛼, have prompted considerable
concern about an increased risk of developing cancer when
they are used on a long-term basis [2, 7, 8]. In contrast,
both DTCM-G and DHMEQ exhibit anticancer activities
against various cancers, including breast, prostate, bladder,
pancreatic, and thyroid cancers, as well as multiple myeloma,
Hodgkin lymphoma, and adult T-cell leukemia [17].
The strong anti-inflammatory activities of DTCM-G and
DHMEQ and the absence of apparent toxicity as well as
their anticancer activities have made them excellent drug
candidates for clinical use in IBDs.
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